These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 18499310)

  • 1. Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
    Goris N; Maradei E; D'Aloia R; Fondevila N; Mattion N; Perez A; Smitsaart E; Nauwynck HJ; La Torre J; Palma E; De Clercq K
    Vaccine; 2008 Jun; 26(27-28):3432-7. PubMed ID: 18499310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
    Maradei E; La Torre J; Robiolo B; Esteves J; Seki C; Pedemonte A; Iglesias M; D'Aloia R; Mattion N
    Vaccine; 2008 Dec; 26(51):6577-86. PubMed ID: 18835312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some guidelines for determining foot-and-mouth disease vaccine strain matching by serology.
    Mattion N; Goris N; Willems T; Robiolo B; Maradei E; Beascoechea CP; Perez A; Smitsaart E; Fondevila N; Palma E; De Clercq K; La Torre J
    Vaccine; 2009 Jan; 27(5):741-7. PubMed ID: 19041355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confidence in indirect assessment of foot-and-mouth disease vaccine potency and vaccine matching carried out by liquid phase ELISA and virus neutralization tests.
    Robiolo B; La Torre J; Maradei E; Beascoechea CP; Perez A; Seki C; Smitsaart E; Fondevila N; Palma E; Goris N; De Clercq K; Mattion N
    Vaccine; 2010 Aug; 28(38):6235-41. PubMed ID: 20643090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of foot and mouth disease vaccine strains--a review.
    Paton DJ; Valarcher JF; Bergmann I; Matlho OG; Zakharov VM; Palma EL; Thomson GR
    Rev Sci Tech; 2005 Dec; 24(3):981-93. PubMed ID: 16642769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle.
    Lavoria MÁ; Di-Giacomo S; Bucafusco D; Franco-Mahecha OL; Pérez-Filgueira DM; Capozzo AV
    Vaccine; 2012 Nov; 30(48):6845-50. PubMed ID: 23000129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM; Bouma A; van den Broek J; Stegeman A; Chénard G; Dekker A
    Vaccine; 2008 Nov; 26(50):6317-21. PubMed ID: 18822336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
    Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
    Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
    Grubman MJ
    Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative.
    Goris N; Willems T; Diev VI; Merkelbach-Peters P; Vanbinst T; Van der Stede Y; Kraft HP; Zakharov VM; Borisov VV; Nauwynck HJ; Haas B; De Clercq K
    Vaccine; 2008 Jul; 26(31):3870-9. PubMed ID: 18555565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immune responses after intra-typic heterologous and homologous vaccination against foot-and-mouth disease virus infection in pigs.
    Eblé PL; de Bruin MG; Bouma A; van Hemert-Kluitenberg F; Dekker A
    Vaccine; 2006 Feb; 24(9):1274-81. PubMed ID: 16289709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences.
    Goris N; Merkelbach-Peters P; Diev VI; Verloo D; Zakharov VM; Kraft HP; De Clercq K
    Vaccine; 2007 Apr; 25(17):3373-9. PubMed ID: 17227691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foot-and-mouth disease marker vaccine: cattle protection with a partial VP1 G-H loop deleted virus antigen.
    Fowler VL; Bashiruddin JB; Maree FF; Mutowembwa P; Bankowski B; Gibson D; Cox S; Knowles N; Barnett PV
    Vaccine; 2011 Oct; 29(46):8405-11. PubMed ID: 21856354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease.
    Mattion N; König G; Seki C; Smitsaart E; Maradei E; Robiolo B; Duffy S; León E; Piccone M; Sadir A; Bottini R; Cosentino B; Falczuk A; Maresca R; Periolo O; Bellinzoni R; Espinoza A; Torre JL; Palma EL
    Vaccine; 2004 Oct; 22(31-32):4149-62. PubMed ID: 15474705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.
    Fowler VL; Knowles NJ; Paton DJ; Barnett PV
    Vaccine; 2010 Apr; 28(19):3428-34. PubMed ID: 20199761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of antibodies to non-structural proteins of foot-and-mouth disease virus in repeatedly vaccinated cattle.
    Lee F; Jong MH; Yang DW
    Vet Microbiol; 2006 Jun; 115(1-3):14-20. PubMed ID: 16446061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage.
    Waters R; Ludi AB; Fowler VL; Wilsden G; Browning C; Gubbins S; Statham B; Bin-Tarif A; Mioulet V; King DJ; Colenutt C; Brown E; Hudelet P; King DP
    Vaccine; 2018 Mar; 36(14):1901-1907. PubMed ID: 29506922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the immune response to FMDV structural and non-structural proteins in cattle in Argentina by the combined use of liquid phase and 3ABC-ELISA tests.
    Robiolo B; Seki C; Fondevilla N; Grigera P; Scodeller E; Periolo O; La Torre J; Mattion N
    Vaccine; 2006 Feb; 24(7):997-1008. PubMed ID: 16171905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cedivac-FMD can be used according to a marker vaccine principle.
    Chénard G; Selman P; Dekker A
    Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.